AI Tokens
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Debt Ratios

Coverage Ratios

Johnson & Johnson, solvency ratios (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Debt Ratios
Debt to equity 0.55 0.58 0.68 0.59 0.58 0.65 0.67 0.51 0.51 0.58 0.48 0.43 0.42 0.61 0.75 0.52 0.43 0.43 0.44
Debt to capital 0.35 0.37 0.40 0.37 0.37 0.39 0.40 0.34 0.34 0.37 0.32 0.30 0.30 0.38 0.43 0.34 0.30 0.30 0.31
Debt to assets 0.23 0.24 0.27 0.24 0.24 0.26 0.27 0.20 0.20 0.23 0.20 0.18 0.18 0.24 0.27 0.21 0.18 0.18 0.19
Financial leverage 2.42 2.37 2.47 2.44 2.43 2.46 2.48 2.52 2.54 2.53 2.46 2.44 2.33 2.55 2.77 2.44 2.35 2.33 2.39
Coverage Ratios
Interest coverage 19.03 25.90 25.00 34.55 36.24 33.48 34.09 23.10 23.92 26.40 29.06 20.51 19.09 23.89 31.49 79.71 141.63 160.27 164.15

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The solvency profile exhibits a transition toward increased leverage and a significant contraction in interest coverage capacity over the analyzed period. While the company maintains a stable foundation, there is a observable shift in the capital structure and a reduction in the margin of safety regarding debt servicing.

Debt-to-Equity, Debt-to-Capital, and Debt-to-Assets Ratios
These three metrics follow a highly correlated trajectory, characterized by an initial period of stability followed by a sharp increase in early 2023. The Debt to Equity ratio peaked at 0.75 in April 2023, representing a substantial increase from the 0.44 observed in April 2022. A similar trend is evident in Debt to Capital, which reached a maximum of 0.43 in the same period, and Debt to Assets, which peaked at 0.27. Following these spikes, the ratios experienced a moderate decline before trending upward again toward 2026, with Debt to Equity reaching 0.68 by March 2026, suggesting a strategic increase in the use of debt relative to equity and total assets.
Financial Leverage
Financial leverage remained relatively stable compared to the debt ratios, fluctuating within a narrow band between 2.33 and 2.77. A peak occurred in April 2023 (2.77), aligning with the spikes in other debt metrics. From mid-2023 through 2026, the leverage ratio stabilized, generally oscillating between 2.37 and 2.54, indicating a consistent approach to the overall multiplier of assets relative to equity.
Interest Coverage Ratio
The most significant volatility is observed in the interest coverage ratio, which underwent a precipitous decline. Starting at 164.15 in April 2022, the ratio dropped sharply throughout 2022 and early 2023, falling to 19.09 by October 2023. After this collapse, the ratio entered a period of relative stabilization, fluctuating between approximately 19.03 and 36.24. Although the current levels remain well above the threshold of concern, the drastic reduction from the initial levels indicates a substantial increase in interest expenses or a decrease in operating income available for debt service.

In summary, the solvency data indicates a deliberate or structural shift toward a more leveraged balance sheet. The concurrent rise in debt ratios and the sharp decline in interest coverage suggest that the company is carrying a higher debt load with a tighter, albeit still sustainable, capacity to service those obligations compared to the 2022 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Equity

Johnson & Johnson, debt to equity calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable 8,852 11,692 17,460 8,495 6,387 11,526 13,897 5,983 4,462 9,855 8,550 3,451 3,870 11,701 17,979 12,771 4,424 4,305 4,297
Long-term debt, excluding current portion 35,799 37,344 37,527 39,438 39,408 39,235 38,355 30,651 31,289 31,636 25,082 25,881 26,051 33,901 34,928 26,888 27,603 28,292 28,851
Total debt 44,651 49,036 54,987 47,933 45,795 50,761 52,252 36,634 35,751 41,491 33,632 29,332 29,921 45,602 52,907 39,659 32,027 32,597 33,148
 
Total Johnson & Johnson shareholders’ equity 81,529 84,971 81,186 81,544 79,277 78,473 78,109 71,490 70,158 71,538 70,020 68,774 71,228 75,149 70,869 76,804 74,599 76,357 74,709
Solvency Ratio
Debt to equity1 0.55 0.58 0.68 0.59 0.58 0.65 0.67 0.51 0.51 0.58 0.48 0.43 0.42 0.61 0.75 0.52 0.43 0.43 0.44
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. — — — — — — 49.22 20.19 11.78 10.42 9.24 5.73 5.02 4.74 4.68 3.67 4.35 4.98 4.51
Amgen Inc. 3.76 4.90 6.24 6.31 5.67 7.57 9.24 10.23 8.02 10.57 12.75 10.37 7.90 9.08 11.52 10.64 10.60 15.10 40.23
Bristol-Myers Squibb Co. 1.83 1.93 2.22 2.44 2.64 2.82 2.86 3.04 2.90 3.08 3.38 1.35 1.30 1.18 1.19 1.27 1.20 1.29 1.42
Danaher Corp. 0.49 0.51 0.35 0.35 0.33 0.33 0.32 0.32 0.34 0.34 0.34 0.34 0.42 0.38 0.39 0.39 0.41 0.43 0.47
Eli Lilly & Co. 1.23 1.62 1.39 1.60 1.79 2.18 2.44 2.37 2.19 2.13 2.05 2.34 1.80 1.70 1.69 1.52 1.58 1.97 1.77
Gilead Sciences Inc. 2.01 2.22 0.94 1.10 1.16 1.27 1.30 1.38 1.26 1.28 1.44 1.09 1.12 1.19 1.20 1.19 1.20 1.30 1.32
Merck & Co. Inc. 1.20 1.29 1.07 0.94 0.80 0.72 0.72 0.80 0.86 0.87 0.85 0.93 0.85 0.95 0.66 0.67 0.68 0.73 0.78
Pfizer Inc. 0.70 0.74 0.72 0.75 0.66 0.70 0.69 0.73 0.73 0.79 0.75 0.81 0.66 0.66 0.36 0.37 0.40 0.46 0.44
Regeneron Pharmaceuticals Inc. 0.08 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.13 0.13 0.14
Thermo Fisher Scientific Inc. 0.76 0.81 0.83 0.74 0.70 0.70 0.69 0.63 0.72 0.75 0.78 0.75 0.78 0.78 0.83 0.78 0.67 0.72 0.81
Vertex Pharmaceuticals Inc. 0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Debt to equity = Total debt ÷ Total Johnson & Johnson shareholders’ equity
= 44,651 ÷ 81,529 = 0.55

2 Click competitor name to see calculations.


The solvency profile is characterized by periodic fluctuations in leverage, with the debt-to-equity ratio moving between a minimum of 0.42 and a maximum of 0.75. While total shareholders' equity has maintained a general upward trajectory from 2024 onward, total debt has exhibited significant volatility, leading to distinct cycles of leverage expansion and contraction.

Total Debt Trends
Total debt levels experienced significant instability, notably peaking at 52.9 billion US dollars in April 2023 and reaching 54.9 billion US dollars in March 2026. Conversely, a sharp reduction in debt was observed during the second half of 2023, with levels falling to a period low of 29.3 billion US dollars by December 31, 2023, before trending upward again through 2024 and 2025.
Shareholders' Equity Evolution
Equity remained relatively stable throughout the analysis period, fluctuating between 68.7 billion and 84.9 billion US dollars. A sustained growth phase began in early 2024, with equity increasing from 70.0 billion US dollars in March 2024 to a peak of 84.9 billion US dollars by June 2026, which served to mitigate the impact of rising debt levels on the overall solvency ratio.
Debt to Equity Ratio Analysis
The debt to equity ratio demonstrated a cyclical pattern of volatility. An initial period of stability between 0.43 and 0.44 was interrupted by a sharp spike to 0.75 in April 2023. Following a correction to 0.42 in October 2023, the ratio entered a secondary phase of increase, reaching 0.67 in December 2024 and peaking at 0.68 in March 2026. The period concluded with a downward correction to 0.55 by September 2026, indicating a reduction in financial leverage toward the end of the observed timeframe.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Capital

Johnson & Johnson, debt to capital calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable 8,852 11,692 17,460 8,495 6,387 11,526 13,897 5,983 4,462 9,855 8,550 3,451 3,870 11,701 17,979 12,771 4,424 4,305 4,297
Long-term debt, excluding current portion 35,799 37,344 37,527 39,438 39,408 39,235 38,355 30,651 31,289 31,636 25,082 25,881 26,051 33,901 34,928 26,888 27,603 28,292 28,851
Total debt 44,651 49,036 54,987 47,933 45,795 50,761 52,252 36,634 35,751 41,491 33,632 29,332 29,921 45,602 52,907 39,659 32,027 32,597 33,148
Total Johnson & Johnson shareholders’ equity 81,529 84,971 81,186 81,544 79,277 78,473 78,109 71,490 70,158 71,538 70,020 68,774 71,228 75,149 70,869 76,804 74,599 76,357 74,709
Total capital 126,180 134,007 136,173 129,477 125,072 129,234 130,361 108,124 105,909 113,029 103,652 98,106 101,149 120,751 123,776 116,463 106,626 108,954 107,857
Solvency Ratio
Debt to capital1 0.35 0.37 0.40 0.37 0.37 0.39 0.40 0.34 0.34 0.37 0.32 0.30 0.30 0.38 0.43 0.34 0.30 0.30 0.31
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 1.06 1.09 1.10 1.05 1.04 1.00 0.98 0.95 0.92 0.91 0.90 0.85 0.83 0.83 0.82 0.79 0.81 0.83 0.82
Amgen Inc. 0.79 0.83 0.86 0.86 0.85 0.88 0.90 0.91 0.89 0.91 0.93 0.91 0.89 0.90 0.92 0.91 0.91 0.94 0.98
Bristol-Myers Squibb Co. 0.65 0.66 0.69 0.71 0.73 0.74 0.74 0.75 0.74 0.75 0.77 0.57 0.56 0.54 0.54 0.56 0.54 0.56 0.59
Danaher Corp. 0.33 0.34 0.26 0.26 0.25 0.25 0.24 0.24 0.25 0.25 0.25 0.26 0.30 0.28 0.28 0.28 0.29 0.30 0.32
Eli Lilly & Co. 0.55 0.62 0.58 0.62 0.64 0.69 0.71 0.70 0.69 0.68 0.67 0.70 0.64 0.63 0.63 0.60 0.61 0.66 0.64
Gilead Sciences Inc. 0.67 0.69 0.49 0.52 0.54 0.56 0.57 0.58 0.56 0.56 0.59 0.52 0.53 0.54 0.55 0.54 0.54 0.56 0.57
Merck & Co. Inc. 0.55 0.56 0.52 0.48 0.44 0.42 0.42 0.44 0.46 0.46 0.46 0.48 0.46 0.49 0.40 0.40 0.41 0.42 0.44
Pfizer Inc. 0.41 0.43 0.42 0.43 0.40 0.41 0.41 0.42 0.42 0.44 0.43 0.45 0.40 0.40 0.26 0.27 0.28 0.32 0.31
Regeneron Pharmaceuticals Inc. 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.12 0.12
Thermo Fisher Scientific Inc. 0.43 0.45 0.45 0.42 0.41 0.41 0.41 0.39 0.42 0.43 0.44 0.43 0.44 0.44 0.45 0.44 0.40 0.42 0.45
Vertex Pharmaceuticals Inc. 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= 44,651 ÷ 126,180 = 0.35

2 Click competitor name to see calculations.


The analyzed period reveals a fluctuating solvency profile characterized by periodic increases in leverage and a general expansion of the total capital base. While the debt-to-capital ratio remained relatively stable during certain intervals, significant spikes indicate episodes of increased borrowing relative to the total capital structure.

Debt to Capital Ratio Trends
The ratio began at 0.31 in April 2022, maintaining stability until a sharp increase to 0.43 in April 2023. This peak was followed by a rapid correction, returning the ratio to 0.30 by December 2023. A second period of increased leverage emerged in late 2024, with the ratio reaching 0.40 in December 2024 and again in March 2026, before moderating to 0.35 by September 2026.
Total Debt Dynamics
Total debt exhibited substantial volatility, ranging from a low of 29.3 billion USD in December 2023 to a peak of 54.9 billion USD in March 2026. Notable increases in debt levels occurred in the first half of 2023 and again throughout early 2026, indicating episodic reliance on debt financing.
Total Capital Evolution
Total capital demonstrated a general upward trajectory, rising from 107.8 billion USD in April 2022 to 126.1 billion USD in September 2026. The capital base reached its maximum of 136.1 billion USD in March 2026, which coincided with the highest recorded debt levels, suggesting that capital growth was heavily influenced by debt accumulation during that specific period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Debt to Assets

Johnson & Johnson, debt to assets calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Loans and notes payable 8,852 11,692 17,460 8,495 6,387 11,526 13,897 5,983 4,462 9,855 8,550 3,451 3,870 11,701 17,979 12,771 4,424 4,305 4,297
Long-term debt, excluding current portion 35,799 37,344 37,527 39,438 39,408 39,235 38,355 30,651 31,289 31,636 25,082 25,881 26,051 33,901 34,928 26,888 27,603 28,292 28,851
Total debt 44,651 49,036 54,987 47,933 45,795 50,761 52,252 36,634 35,751 41,491 33,632 29,332 29,921 45,602 52,907 39,659 32,027 32,597 33,148
 
Total assets 197,425 201,061 200,894 199,210 192,816 193,389 193,671 180,104 178,287 181,088 171,966 167,558 166,061 191,686 195,969 187,378 175,124 177,724 178,355
Solvency Ratio
Debt to assets1 0.23 0.24 0.27 0.24 0.24 0.26 0.27 0.20 0.20 0.23 0.20 0.18 0.18 0.24 0.27 0.21 0.18 0.18 0.19
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.55 0.52 0.53 0.50 0.51 0.51 0.51 0.50 0.50 0.50 0.50 0.44 0.45 0.45 0.46 0.46 0.49 0.51 0.51
Amgen Inc. 0.56 0.60 0.62 0.60 0.61 0.64 0.64 0.65 0.66 0.69 0.69 0.67 0.67 0.68 0.69 0.60 0.61 0.62 0.62
Bristol-Myers Squibb Co. 0.48 0.49 0.51 0.50 0.51 0.52 0.54 0.54 0.53 0.55 0.56 0.42 0.41 0.40 0.40 0.41 0.40 0.42 0.44
Danaher Corp. 0.28 0.29 0.22 0.22 0.21 0.21 0.21 0.21 0.22 0.22 0.22 0.22 0.25 0.23 0.23 0.23 0.24 0.25 0.26
Eli Lilly & Co. 0.33 0.39 0.37 0.38 0.37 0.40 0.43 0.43 0.41 0.40 0.41 0.39 0.35 0.34 0.36 0.33 0.33 0.36 0.35
Gilead Sciences Inc. 0.51 0.53 0.39 0.42 0.43 0.45 0.44 0.45 0.43 0.44 0.45 0.40 0.40 0.40 0.41 0.40 0.40 0.42 0.42
Merck & Co. Inc. 0.41 0.42 0.38 0.36 0.32 0.30 0.30 0.32 0.32 0.34 0.32 0.33 0.33 0.35 0.29 0.28 0.28 0.30 0.30
Pfizer Inc. 0.31 0.31 0.31 0.31 0.30 0.30 0.30 0.30 0.31 0.32 0.31 0.32 0.30 0.30 0.18 0.18 0.19 0.21 0.20
Regeneron Pharmaceuticals Inc. 0.06 0.06 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10
Thermo Fisher Scientific Inc. 0.36 0.38 0.38 0.36 0.35 0.35 0.35 0.32 0.35 0.36 0.37 0.35 0.36 0.36 0.37 0.35 0.32 0.33 0.36
Vertex Pharmaceuticals Inc. 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= 44,651 ÷ 197,425 = 0.23

2 Click competitor name to see calculations.


The analysis of solvency metrics reveals a period of fluctuation in leverage, characterized by cyclical increases and decreases in total debt relative to the total asset base.

Debt to Assets Ratio Trends
The ratio exhibited a volatile pattern, ranging from a minimum of 0.18 to a maximum of 0.27. Two distinct peaks at 0.27 occurred in April 2023 and March 2026, indicating periods of increased financial leverage. A period of relative stability and lower leverage is noted between October 2022 and October 2023, during which the ratio reached its floor of 0.18.
Total Debt Dynamics
Total debt levels experienced significant volatility, starting at 33,148 million USD in April 2022 and reaching a peak of 54,987 million USD by March 2026. A notable surge is evident in early 2023, where debt climbed to 52,907 million USD in April before a sharp contraction to 29,332 million USD by December 2023.
Total Asset Trajectory
Total assets demonstrated a general upward trajectory, increasing from 178,355 million USD in April 2022 to a peak of 201,061 million USD in June 2026. A significant temporary contraction occurred in October 2023, where assets decreased to 166,061 million USD, coinciding with a simultaneous reduction in total debt.

Overall, the financial structure indicates a variable approach to leverage. The debt-to-assets ratio remained consistently below 0.30 throughout the observed period, suggesting a maintained solvency buffer despite periodic spikes in borrowing.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Financial Leverage

Johnson & Johnson, financial leverage calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Total assets 197,425 201,061 200,894 199,210 192,816 193,389 193,671 180,104 178,287 181,088 171,966 167,558 166,061 191,686 195,969 187,378 175,124 177,724 178,355
Total Johnson & Johnson shareholders’ equity 81,529 84,971 81,186 81,544 79,277 78,473 78,109 71,490 70,158 71,538 70,020 68,774 71,228 75,149 70,869 76,804 74,599 76,357 74,709
Solvency Ratio
Financial leverage1 2.42 2.37 2.47 2.44 2.43 2.46 2.48 2.52 2.54 2.53 2.46 2.44 2.33 2.55 2.77 2.44 2.35 2.33 2.39
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. — — — — — — 95.89 40.65 23.78 20.94 18.59 13.00 11.26 10.52 10.14 8.04 8.84 9.77 8.80
Amgen Inc. 6.69 8.18 10.07 10.46 9.37 11.83 14.40 15.63 12.07 15.34 18.51 15.59 11.83 13.31 16.59 17.79 17.44 24.51 64.62
Bristol-Myers Squibb Co. 3.79 3.93 4.31 4.87 5.22 5.43 5.32 5.67 5.46 5.56 6.01 3.23 3.15 2.92 2.96 3.12 3.01 3.08 3.26
Danaher Corp. 1.74 1.76 1.58 1.59 1.56 1.56 1.56 1.57 1.57 1.57 1.56 1.58 1.67 1.64 1.65 1.68 1.72 1.76 1.80
Eli Lilly & Co. 3.68 4.20 3.74 4.24 4.83 5.52 5.67 5.55 5.31 5.30 4.99 5.94 5.16 4.95 4.75 4.65 4.71 5.51 5.03
Gilead Sciences Inc. 3.94 4.17 2.39 2.60 2.72 2.83 2.95 3.05 2.95 2.93 3.21 2.72 2.80 2.95 2.95 2.97 2.97 3.11 3.17
Merck & Co. Inc. 2.96 3.10 2.80 2.60 2.50 2.40 2.38 2.53 2.64 2.58 2.62 2.84 2.59 2.70 2.30 2.37 2.41 2.48 2.61
Pfizer Inc. 2.30 2.36 2.30 2.41 2.25 2.32 2.30 2.42 2.38 2.47 2.40 2.54 2.22 2.22 1.94 2.06 2.10 2.24 2.23
Regeneron Pharmaceuticals Inc. 1.33 1.32 1.30 1.30 1.30 1.28 1.28 1.29 1.28 1.28 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32
Thermo Fisher Scientific Inc. 2.09 2.15 2.18 2.07 2.02 2.00 2.01 1.96 2.05 2.08 2.13 2.11 2.14 2.15 2.24 2.21 2.08 2.14 2.26
Vertex Pharmaceuticals Inc. 1.57 1.35 1.37 1.37 1.44 1.40 1.39 1.37 1.42 1.36 1.29 1.29 1.32 1.32 1.31 1.30 1.28 1.31 1.31

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Financial leverage = Total assets ÷ Total Johnson & Johnson shareholders’ equity
= 197,425 ÷ 81,529 = 2.42

2 Click competitor name to see calculations.


The financial leverage of the organization exhibits a high degree of stability over the analyzed period, generally oscillating between 2.33 and 2.54. While there was a notable peak in early 2023, the overall capital structure has remained consistent, indicating a disciplined approach to balancing debt and equity relative to the asset base.

Asset Base Fluctuations
Total assets demonstrated a volatile but generally upward trajectory. A significant contraction occurred between July 2, 2023, and October 1, 2023, where assets decreased from 191,686 million to 166,061 million. Following this trough, a steady recovery was observed, with assets peaking at 201,061 million in June 2026 before slightly moderating to 197,425 million by September 2026.
Shareholders' Equity Trends
Shareholders' equity remained relatively stable throughout most of the period, with a gradual decline from 74,709 million in April 2022 to a low of 68,774 million by December 31, 2023. This was followed by a period of expansion, reaching a peak of 84,971 million in March 2026. The equity levels ended the period at 81,529 million, representing a modest net increase from the start of the observed timeline.
Financial Leverage Ratio Dynamics
The financial leverage ratio remained largely constrained within a narrow range. The highest leverage peak occurred on April 2, 2023, reaching 2.77, which coincided with a period of asset growth and a simultaneous dip in equity. Subsequently, the ratio normalized, spending the majority of the 2024 and 2025 periods between 2.42 and 2.54. The ratio concluded the period at 2.42, suggesting that the growth in total assets has been funded proportionally by equity and liabilities, maintaining a constant risk profile regarding solvency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Interest Coverage

Johnson & Johnson, interest coverage calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Net earnings (loss) 210 5,534 5,235 5,116 5,152 5,537 10,999 3,431 2,694 4,686 3,255 4,049 26,028 5,144 (68) 3,520 4,458 4,814 5,149
Less: Net earnings (loss) from discontinued operations, net of tax — — — — — — — — — — — (83) 21,719 (232) 423 — — — —
Add: Income tax expense (176) 1,213 755 (150) 2,341 954 2,632 456 644 1,062 459 694 908 930 (796) 681 1,364 1,026 713
Add: Interest expense, net of portion capitalized 217 281 272 214 245 308 204 137 193 270 155 151 192 217 212 177 51 38 10
Earnings before interest and tax (EBIT) 251 7,028 6,262 5,180 7,738 6,799 13,835 4,024 3,531 6,018 3,869 4,977 5,409 6,523 (1,075) 4,378 5,873 5,878 5,872
Solvency Ratio
Interest coverage1 19.03 25.90 25.00 34.55 36.24 33.48 34.09 23.10 23.92 26.40 29.06 20.51 19.09 23.89 31.49 79.71 141.63 160.27 164.15
Benchmarks
Interest Coverage, Competitors2
Amgen Inc. 5.19 4.86 4.38 4.26 3.89 3.53 3.18 2.46 2.45 2.10 2.38 3.73 4.54 5.43 6.51 6.22 6.83 6.97 6.40
Danaher Corp. 14.38 17.31 17.95 16.97 16.41 15.01 16.80 17.71 16.11 17.61 17.81 18.64 23.66 29.65 35.60 40.30 41.32 35.26 33.54
Gilead Sciences Inc. -1.51 -0.96 11.68 10.57 10.71 8.20 7.94 1.71 1.18 2.58 2.11 8.27 8.88 9.03 8.84 7.22 5.80 6.73 6.97
Regeneron Pharmaceuticals Inc. 122.77 94.25 108.44 120.42 123.21 134.19 105.27 87.59 79.88 69.47 57.85 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24
Thermo Fisher Scientific Inc. 6.10 6.17 6.03 6.12 6.19 6.09 6.25 6.03 5.62 5.62 5.53 5.54 5.98 6.64 8.28 11.56 13.59 15.70 16.73
Vertex Pharmaceuticals Inc. 122.10 800.17 502.52 350.11 348.55 258.29 -11.94 9.12 7.76 6.14 111.61 100.32 96.54 90.90 82.27 78.23 70.08 66.72 48.17

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q3 2026 Calculation
Interest coverage = (EBITQ3 2026 + EBITQ2 2026 + EBITQ1 2026 + EBITQ4 2025) ÷ (Interest expenseQ3 2026 + Interest expenseQ2 2026 + Interest expenseQ1 2026 + Interest expenseQ4 2025)
= (251 + 7,028 + 6,262 + 5,180) ÷ (217 + 281 + 272 + 214) = 19.03

2 Click competitor name to see calculations.


The analysis of solvency indicators reveals a significant contraction in the interest coverage ratio over the observed period, characterized by an initial steep decline followed by a period of relative stabilization and subsequent volatility.

Earnings Before Interest and Tax (EBIT) Trends
Operating earnings exhibited substantial volatility. Following a period of relative stability in 2022, a significant contraction occurred in April 2023, where EBIT fell to negative 1,075 million US$. A notable peak was recorded in March 2025, reaching 13,835 million US$, before a sharp decline to 251 million US$ by September 2026. These fluctuations indicate inconsistent operating performance impacting the company's ability to service debt.
Interest Expense Dynamics
Net interest expenses experienced a rapid escalation between April 2022 and April 2023, rising from 10 million US$ to 212 million US$. For the remainder of the period, interest costs remained elevated, generally fluctuating between 137 million US$ and 308 million US$. This sustained increase in the cost of debt servicing created a higher threshold for operating earnings to maintain solvency ratios.
Interest Coverage Ratio Performance
The interest coverage ratio underwent a dramatic reduction, falling from a high of 164.15 in April 2022 to 19.09 by October 2023. This decline was driven by the simultaneous increase in interest expenses and volatility in EBIT. From late 2023 through mid-2025, the ratio stabilized within a range of 23.10 to 36.24. However, a downward trend resurfaced in 2026, ending at 19.03 in September 2026, coinciding with the significant drop in quarterly EBIT.

In summary, while the interest coverage ratio remains well above the critical threshold of 1.0, the long-term trajectory shows a marked decrease in the margin of safety. The company's solvency position became more sensitive to operating earnings volatility as the baseline for interest expenses shifted permanently higher starting in 2023.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?